Edwards Lifesciences halts enrolment in Cardiaq trial

The Edwards Lifesciences Cardiaq device

According to a SeekingAlpha transcript of an Edwards Lifesciences fourth-quarter 2016 earnings conference call, the company has put a halt on enrolment in its clinical trial of Cardiaq.

“We recently paused enrolment in our clinical trials to perform further design validation testing on a feature of our valve,” Michael A Mussallem said during the call. “If we see positive results from the test, we expect to resume clinical trial enrolment in the second quarter [of 2017]. This pause also postpones the start of our CE mark trial.”

According to the call, this was consistent with “clinical learnings” from the US feasibility study of the device. “It’s a bit of a signal of just how early this therapy is,” Mussallem said. “in every case [we learn] not only something about our device, [but] something about the procedure, something about imaging, and something about anticoagulation, and we are trying to apply all those learnings as we go.”

A press release entitled reporting Edwards’ financial results, released on 1st February—hours before the conference call—does not mention the Cardiaq issue.

Edwards LifeSciences purchased Cardiaq Valve Technologies in 2015.

(Visited 223 times, 1 visits today)